HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bayer’s Innovation Engine Shifts Up A Gear To Propel Turnaround

Executive Summary

Bayer stepped up its Consumer Health innovation efforts in 2020 in line with its turnaround plan for the business, and now has more than 100 projects in development.

You may also be interested in...



Bayer Consumer Health Looks To India And China For New Sources Of Growth

Bayer Consumer Health is stepping up investments in India, China and South East Asia to unleash untapped potential in these high growth OTC markets. 

Bayer ‘Outperforming’ Market As Turnaround Plan Bears Fruit

Bayer says its Consumer Health sales grew at twice the rate of the market in Q3, thanks to a number of operational changes instituted by business head Heiko Schipper back in 2018.

Bayer Steps Up Skin Microbiome Research For Cosmetics With Partner Azitra

Bayer invests $8m in medical dermatology specialist Azitra to advance development of OTC and cosmetic products harnessing the skin microbiome.

Related Content

Topics

UsernamePublicRestriction

Register

RS151066

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel